Exploratory study of intravenous L-carnitine in fatigue-improvement on the patients bearing endstage cancer

Exploratory study of intravenous L-carnitine in fatigue-improvement on the patients bearing endstage cancer - Exploratory study of intravenous L-carnitine in fatigue-improvement on the patients bearing endstage cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027078

Enrollment

Registered

2017-04-22

Start date

2017-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignancy

Interventions

One thousand milligram per day of L-Cartin FF(TM) injection is given for seven consecutive days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients bearing endstage cancer hospitalized at palliative care unit Appeal for fatigue Agreement of the attending research doctor

Exclusion criteria

Exclusion criteria: More than a symptom except fatigue are/is not relieved Three days have not passed from hospitalization in palliative care unit Change in the opioids doses within three days before entry Change in adrenocorticosteroid doses within three days before entry An intravenous feeding route is not secured

Design outcomes

Primary

Measure	Time frame
Cancer Fatigue Scale	—

Secondary

Measure	Time frame
Numeric rating scale of fatigue Objective evaluation by the medical staff	—

Countries

Japan

Contacts

Public ContactJunko Nakanishi

Mitoyo General Hospital Department of pharmaceutical services

junko-ph@mitoyo-hosp.jp0875-52-3366

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026